EGFR and non-small cell lung carcinoma: The 80-mg daily dose evaluated in the phase II T790M+ extension cohort of the AURA trial (described above) was evaluated in an additional phase II “AURA2” study (NCT02094261) designed for patients with confirmed EGFR-mutant T790M+ locally advanced or metastatic NSCLC progressing on an approved EGFR TKI.